Can MRI predict dangerous heart rhythms in mitral valve prolapse?
NCT ID NCT04852731
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 280 people with mitral valve prolapse over 3 years to see if heart MRI scans and blood tests can predict who will develop dangerous heart rhythms or heart muscle changes. Participants undergo MRI, blood draws, and heart monitoring. The goal is to find early warning signs for serious complications.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify which mitral valve prolapse patients are at higher risk for dangerous heart rhythms, leading to better monitoring and earlier treatment.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new drug or therapy, and the findings may not lead to immediate changes in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 280 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2021
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient over 18 years old, * Patient with mitral valve prolapse, * Patient who has received full information about the organization of the research and has signed an informed consent, * Patient affiliated to or beneficiary of a social security insurance, * Patient who has completed a prior clinical examination adapted to the research and who does not show any contraindication to the planned examinations Exclusion Criteria: * Stage of the disease: Patients with MVP with severe mitral regurgitation with a surgical indication as defined by current recommendations will not be included in the study, * Presence of severe rhythm disorders requiring the implantation of a defibrillator (cardiorespiratory arrest recovered, sudden death recovered, etc.), * Performance of an injected MRI in the month preceding the MRI scheduled during visit n°1, * Previously diagnosed cardiopathy that may be responsible for myocardial damage (ventricular remodeling, alteration of left ventricular systolic function, fibrosis, etc.) and that may disrupt the interpretation of results (infarction, amyloidosis, systemic scleroderma, significant aortic valvulopathy, etc.). * Contraindication to MRI examination, particularly in the presence of an implantable pacemaker or defibrillator, implanted pump, cochlear implants, neurosurgical clips, intraorbital or encephalic metallic foreign bodies, * Claustrophobia or morphotype that does not allow MRI to be performed, * Motor or mental disability, * Renal impairment that does not allow the injection of Gadolinium-based contrast media (DOTAREM® or equivalent in the study). If there is any doubt as to the patient's renal function, a plasma creatinine determination will be performed for MRI to ensure the absence of renal failure, * Hypersensitivity to gadoteric acid, meglumine, or any gadolinium-containing drug. * Women of childbearing age who do not have effective contraception, * Persons referred to in Articles L. 1121-5 to L1121-8 of the Public Health Code.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mitral valve prolapse are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nancy University Hospital
Vandœuvre-lès-Nancy, 54511, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can imaging and monitoring unlock the hidden dangers of mitral valve prolapse?
- Heart valve repair showdown: which surgery works best?
- AI reads heart scans to help surgeons fix leaky valves
- New study aims to predict dangerous heart scarring in common valve condition
- Heart MRI may outshine ultrasound for valve surgery timing
- Heart monitoring breakthrough: 14 days vs. 24 hours for MVP patients